Company: CNTB
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001835268-25-000035
Chunk: 10

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 10
---
, net:Interest income720 1,247 Other income, net509 2,723 Total other income, net1,229 3,970 Net loss before income tax(10,218)(8,663)Income tax expense54 30 Net loss$(10,272)$(8,693)Other comprehensive loss:Foreign currency translation adjustments62 (234)Unrealized (losses) gains on available-for-sale investments(1)9 Comprehensive loss$(10,211)$(8,918)Basic and diluted net loss per ordinary share$(0.19)$(0.16)Weighted-average ordinary shares outstanding, basic and diluted55,352 55,103 

See accompanying notes.

5

TABLE OF CONTENTS

CONNECT BIOPHARMA HOLDINGS LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(Unaudited)

(in thousands)

Ordinary SharesAdditional Paid-In CapitalAccumulated Other Comprehensive LossTreasuryAccumulatedDeficitTotal Shareholders' EquitySharesAmountSharesBalance, December 31, 202455,349$10 $439,357 $(1,666)$(180)$(345,355)$92,166 Issuance of ordinary shares upon exercise of stock options3— 2 — — — 2 Share-based compensation expense— — 942 — — — 942 Net loss— — — — — (10,272)(10,272)Net unrealized losses on available-for-sale investments— — — (1)— — (1)Foreign currency translation adjustments— — — 62 — — 62 Balance, March 31, 202555,352$10 $440,301 $(1,605)$(180)$(355,627)$82,899 

Ordinary SharesAdditional Paid-In CapitalAccumulated Other Comprehensive LossTreasuryAccumulated DeficitTotal Shareholders' EquitySharesAmountSharesBalance, December 31, 202355,013$10 $432,402 $(1,008)$(180)$(329,727)$101,497 Share-based compensation expense— — 1,316 — — — 1,316 Net loss— — — — — (8,693)(8,693)Net unrealized gains on